ROSSARI BIOTECH LIMITED Fair Value
ROSSARI · Chemicals · Current price ₹476.95
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹236 | 11% ROE fading to 13% over ~3 yrs, on ₹241 book |
| Relative P/E | ₹1,218 | EPS × 45.2 peer-median P/E |
| Graham floor | ₹382 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹611 | Street consensus 12-month target price |
Is ROSSARI BIOTECH LIMITED undervalued?
DocStoX estimates the fair value of ROSSARI BIOTECH LIMITED at ₹537 per share, versus the current market price of ₹477. That puts the stock about +12.5% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹236), Relative P/E (₹1,218), Graham floor (₹382), Analyst target (₹611). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹236 (bear) to ₹537 (base) to ₹1,218 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ROSSARI BIOTECH LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.